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ABSTRACT 
Individuals having Genetic Thrombophilia pose a higher risk of having a thrombotic 
event. It is crucial to determine these gene variants to prevent a possible episode of 
thromboembolism. With the current PCR method, it involves individual processing of DNA 
isolation, amplification, and detection using three (3) different instruments resulting to an 
increased turnaround time of 5 to 7 days and additional staff utilization. It is performed by 
repetitive manual sample pipetting and preparation of reagent master mixes in small vials. 
Results interpretations are entered manually to a worklist built initially for final verification. 
These processes increase the risk of staff injury and potential result error that could impact 
patient management. 
The introduction of the GeneXpert technology by Cepheid will aid in the prevention of 
staff injury from repetitive motion, improve the turnaround time and eliminate potential risk of 
error. This test system performs DNA isolation, amplification and detection within a cartridge kit 
that will decrease instrument preventive maintenance costs and personnel hands-on utilization. 
Furthermore, an individualized quality control plan (IQCP) will be implemented after risk 
assessment of the pre-analytic, analytic and post-analytic phase of testing to customize quality 
control frequency ensuring the accuracy of test results upon approval by the Laboratory director. 
A combination of 104 whole blood samples of sodium citrate (83) and EDTA (21) that 
were previously tested with the current method was used for the validation study.  Fifteen (15) of 
the whole blood citrate samples were frozen after testing to confirm the manufacturer's claim of 
an alternative sample. Seventy-nine (100%) whole blood citrate samples and twenty-one (100%) 
whole blood EDTA samples were correlated with the results of the current PCR method.  
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INTRODUCTION 
Genetic thrombophilia is the most common hereditary disorder that increases the 
likelihood occurrence of thrombosis. It can be identified with a significant minority of patients 
with venous thromboembolism and in most patients with well-known thrombotic episodes 
(Murin, Marelich, Arroliga, & Matthay, 1998). 
There are also other endogenous anticoagulant deficiencies such as Protein C, Protein S 
and Antithrombin that have been determined to cause hypercoagulable state, but the incidence is 
low with patients with familial thrombosis. As a result of extensive research and study, it was 
discovered that resistance to activated protein C (APC) is the most common genetic risk factor 
for venous thrombosis. It is caused by a single point mutation in the factor V gene. A gene that 
transcribes the protein called coagulation factor V. These coagulation factors is a  group of 
related proteins that make up the coagulation system that is responsible for the formation of 
blood clots after an injury and trigger blood vessel repair (Genetics Home Reference, n.d.). 
Another important type of hereditary thrombophilia is a variant that occurs in the prothrombin 
gene at allele 20210 (PT20210), its prevalence and association of thrombosis is not as high 
compared Factor V Leiden but is significant. The most common clinical manifestation is deep 
vein thrombosis (DVT) thus, the increased ability to determine underlying risk factors with 
thrombotic patients will enable to perform immediate testing with these genetic variants. 
The detection of the Factor V Leiden mutation and PT20210 allele are best performed 
using point mutation real-time PCR analysis due to technique simplicity and allows 
differentiation from rare variants (Peter C. Cooper & Anne C. Goodeve, 2012). 
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ACTIVATED PROTEIN C RESISTANCE (FACTOR V LEIDEN) 
The factor V allele is resistant to the 
proteolytic effect of Protein C in patients with 
activated protein C resistance. This resistance 
is due to the transition of guanine to adenine at 
nucleotide position 1691 (G1691), a gene 
product called Factor V Leiden. The single 
point mutation in the Factor V gene resulting in a 
substitution of arginine with glutamine at position 
506 in one of the protein cleavage sites and renders activated Factor V resistant to cleavage and 
the inability to deactivate Factor V and Factor  VIII in the coagulation cascade causing increased 
formation of thrombin resulting to clot formation. (Figure 1).  
The presence of this mutation will result in a 5-10fold increase for heterozygote carriers 
and approximately 50 -100fold in homozygotes risk of venous thrombosis which occurs 20-60% 
of APC resistant individuals. The FV mutation is prevalent from 1-15% in a population of 
Caucasian origin (Zöller, Hillarp, Berntorp, & Dahlbäck, 1997). 
PROTHROMBIN 20210A MUTATION 
The activation of Factor V and Factor VIII by precursor prothrombin converts fibrinogen 
to fibrin. It has been identified the transition from guanine (G) to adenine (A) at the last 
nucleotide position 20210 in the 3’- untranslated region of the gene (figure 2) that is associated 
FIGURE 1 SIMPLIFIED COAGULATION CASCADE & 
PROTEIN C ANTICOAGULATION SYSTEM 
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with an increased risk for venous 
thrombosis. Having the 20210A allele 
causes marked increase levels of 
plasma prothrombin. (Poort SR, 1996) 
Heterozygotes have a 2-5fold 
increase risk of thrombosis and with the presence 
of other forms of thrombophilia will significantly increase thrombotic risk. Homozygotes are 
rarely occurring in less than 1% of the population. 
Historically, laboratory testing for thrombophilia focuses on the detection of the 
endogenous anticoagulant deficiencies of Protein C, Protein S and Antithrombin, 
dysfibrinogenemia and antiphospholipid antibodies (APA)/lupus anticoagulants (LA) but for the 
past decade, venous thromboembolism has been so complex that because of its heterogeneity, 
diagnosis is dependent on both acquired and genetic factors. In this regard, the mutation 
determination of FV Leiden and PT20210 gene is highly significant in the pathogenesis of DVT 
in combination with acquired factors such as trauma, pregnancy, surgery, age, weight, etc. 
Coexistence of both mutations of Factor V Leiden and PT 20210 are found in 10% of the 
population with predetermined thrombotic episodes. (Vicente R et al, 1999) 
FIGURE 2 G (20210) A PROTHROMBIN GENE 
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MATERIALS AND METHODS 
INSTRUMENTATION 
An FDA approved, closed platform GeneXpert system by 
Cepheid (Figure 3) that performs qualitative real-time PCR 
for automated detection and genotyping of Factor  
V Leiden and PT20210 alleles directly from whole blood 
samples. The test is intended to perform DNA isolation, 
amplification, and detection in a cartridge kit with a 
turnaround time of 30 minutes for each testing. A sample volume of 50ul of whole blood is 
dispensed straight into the bottom of the cartridge. Each cartridge (Figure 4) includes internal 
quality controls and contains freeze-dried beads with necessary components for PCR such as 
DNA polymerase, nucleotides, primers and scorpion probes.  Through the PCR cycles, the 
specific binding of the probe sequence to the target mutation detected at real time and allows the 
software to report out both FV and PT20210 in approximately thirty-two (32) minutes. 
 
FIGURE 4 CARTRIDGE KIT 
FIGURE 3 GENEXPERT SYSTEM 
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VALIDATION STUDY 
A combination of 104 whole blood of sodium citrate and EDTA samples that were 
previously tested using current invader assay method was processed with the GeneXpert 
technology system. Most of these samples were stored at 2-8C and stable for 15 days and some 
samples were stored at room temperature with a 24hour stability. Additionally, 15 frozen citrate 
samples were tested to verify its suitability for testing as recommended by the manufacturer. 
Precision studies consist of four (4) Sodium citrate samples consisting of one (1) normal 
sample for both FV Leiden and PT20210, one (1) heterozygous sample for PT20210, one (1) 
heterozygous sample for FV Leiden and one (1) homozygous sample for both FV Leiden and 
PT20210. These 4 samples were run in duplicate for 5 days. 
Correlation studies were performed with eighty-five (85) whole blood samples, a 
combination of sixty-four (64) citrate tubes and twenty-one (21) EDTA samples. The samples 
included two (2) homozygous FV Leiden, one (1) homozygous PT20210, thirty-seven (37) 
Heterozygous FV Leiden, thirty-one (31) normal FV Leiden, seventeen (17) heterozygous 
PT20210 and fifty-one (51) normal PT20210. Fifteen (15) frozen citrate samples were also tested 
for possible consideration of using this type of sample for testing as stated by the manufacturer. 
INDIVIDUALIZED QUALITY CONTROL PLAN 
According to the Clinical Laboratory Improvement Amendments (CLIA) of 1988, 
laboratories are required to have Quality Control procedures to monitor the accuracy and 
reliability of test results. A minimum of 2 levels of controls must be performed every eight hours 
of patient testing. IQCP provides a foundation for an alternative quality control (QC) program 
that would allow laboratories, after appropriate assessment, the choice to implement a 
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customized QC plan for specific tests utilizing internal control systems. By performing the steps 
of IQCP, it will evaluate the potential sources of error in the three (3) phases of testing and 
establish an appropriate QC and best practices to prevent possible errors. After the evaluation 
process, other potential sources of error might be determined and that may require additional QC 
activities resulting in a more comprehensive QC program.  
IQCP consists of 3 parts: Risk assessment (RA), Quality control plan (QCP) and Quality 
Assessment (QA). 
1.RISK ASSESSMENT (RA) 
 Identification and evaluation of the risk that occurs in the preanalytical, analytical and 
post-analytical phases of testing. There are six (6) components that need to be evaluated for Risk 
assessment for potential sources of error and possible failures. These are Specimen, Test System, 
Reagents, Environment, Testing personnel, and Test results.  
Lists of information to conduct Risk Assessment (RA) 
 Laboratory policies and procedures 
 CAP Checklists- Common Checklist and Molecular Pathology 
 Manufacturer’s package inserts (intended use, reagent, QC frequency, maintenance, 
environment, et al) 
 Method Validation records 
 Laboratory records (QC, PT, New lot verification, Maintenance) 
 Error correction and Provider complaints 
 Personnel Training and competency records 
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Based on the information listed, a table summary of Risk assessment (Table 7) was 
established for possible sources of error or failures consisting of the six (6) elements in 
relation to the different phases of testing. It is evaluated according to Risk level (Table 1) and 
Risk acceptability (Table 2). 
TABLE 1 DETERMINATION OF RISK LEVEL 
Frequency of Occurrence Severity of Harm  
Unlikely (once every 2-3 years) Negligible (temporary discomfort) 
Occasional (once every year) Minor (temporary injury; not requiring 
medical intervention 
Probable (once per month) Serious (impairment, requiring medical 
intervention 
Frequent (once a week) Critical (life-threatening consequences) 
*Unknown (detectable but the frequency is 
unknown 
 
**Undetectable (unable to detect)  
 
*Unknown = Frequency of occurrence is unknown. No documentation/data collected. 
**Undetectable = Unable to detect error unless by direct observation. (e.g. improper collection) 
TABLE 2 RISK ACCEPTABILITY MATRIX 
2. QUALITY CONTROL PLAN 
A Quality Control Plan (QCP) describes practices, procedures, and resources needed by 
the laboratory to ensure the quality of a testing process. The QCP includes measures to assure the 
Probability of 
Harm 
Negligible Minor Serious Critical 
Frequent Not Acceptable Not Acceptable Not Acceptable Not Acceptable 
Probable Acceptable Not Acceptable Not Acceptable Not acceptable 
Occasional Acceptable Acceptable Acceptable Not acceptable 
Unlikely Acceptable Acceptable Acceptable Acceptable 
Unknown Not Acceptable Not Acceptable Not Acceptable Not Acceptable 
Undetectable Not Acceptable Not Acceptable Not Acceptable Not Acceptable 
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accuracy and reliability of test results, and that the quality of testing is adequate for patient care. 
The QCP must provide for immediate detection of errors that occur due to test system failure, 
adverse environmental conditions, and operator performance. It must also monitor, over time, the 
accuracy and precision of test performance that may be influenced by changes in the specimen, 
test system, reagent, environment, or variance in operator performance.  
This QCP is fulfilled through the creation of written standard operating procedures for 
instrumentation, maintenance, quality assurance and reviews involving historical quality control 
review, historical proficiency testing review, test system information and all the information used 
to conduct the risk assessment. 
  Each cartridge contains internal controls that check every step of the assay that validates 
the system, test reagents, sample, lysis, amplification and integrity of the cartridge itself. 
External controls were purchased from Maine molecular Quality control Inc and were run thru a 
31-day period (College of American Pathologist, Common checklist, n.d.). It is used to verify the 
accuracy and precision of the Cepheid GeneXpert analyzer. In an unopened bottle of external 
controls, it will last until the indicated expiration date when stored at 2C – 8C. In an open bottle, 
the controls were stable for 30 days. In the event of any QC failure, QC must be repeated with 
appropriate documentation and corrective action performed. A patient look-back will be 
performed if QC continues to fail and will immediately be addressed to Manufacturer’s technical 
support for evaluation. For repeated results that are not in agreement, an error correction report 
will be performed, appropriate investigations and corrective actions will be implemented to 
verify instrument performance and accuracy of results. 
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3. QUALITY ASSESSMENT (QA) 
Quality assessment is a continuous process of monitoring the effectiveness of the Quality 
control plan for error prevention and detection. QCP and QA will be updated when new sources 
of errors or failures are identified. Non-conformance and/or procedure deviation will be 
addressed with affected personnel by the laboratory management for appropriate corrective 
action(s). A review system mechanism will be established that details ongoing activities for 
monitoring the effectiveness of the QCP. The mechanism of Quality assurance includes: 
 Verification of new lot reagent kit -test with 5 patient samples paralleled against 
a current lot of reagent with results within acceptable criteria. 
 Training of personnel- completed all the applicable training checklists and 
comprehension of test procedures, signed off by Quality supervisor/manager 
 Competency Assessment- performed at initial orientation, after 6 months and 
annual evaluation. 
 Proficiency Testing- Performance of PT survey (TPM from CAP) includes 
handling by staff and PT failure investigation if needed. 
 Error Correction reports (ECR) -Refer to the specific binder 
 Medical record or Test error correction request 
 Physician inquiries- document any clinician concern/or feedback 
 Population statistics- Monthly report compared with historical statistics and 
maintained in quality control indicator folder. Acceptable criteria are 2 SD of 
historical results.  
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RESULTS 
The precision or reproducibility study consisted of four (4) sample types: one (1) sample 
normal for both FV Leiden and PT20210, two (2) samples for each heterozygous FV Leiden and 
PT20210 and one (1) homozygous type for both FV Leiden and PT20210. These samples were 
run in duplicate for 5 days and were all 100% in agreement with the expected result (Table 3). 
For the accuracy study, a combination of sixty-eight (68) Sodium Citrate and EDTA samples 
were used for correlation, all results obtained were 100% in agreement with the results of the 
previous method. (Table 4) 
Table 3 Precision Summary in duplicates x 5 days 
Specimen ID Obtained result Expected Result % Total Agreement 
Normal (FVL 
/PT20210 
Normal/Normal Normal/Normal 100% (10/10) 
Heterozygous (FVL) Heterozygous Heterozygous 100% (10/10) 
Heterozygous 
(PT20210) 
 
Heterozygous 
 
Heterozygous 
 
100% (10/10) 
Homozygous 
(FVL/PT20210) 
Homozygous/ 
Homozygous 
 
Homozygous/ 
Homozygous 
 
 
100% (10/10) 
 
 
TABLE 4 CORRELATION SUMMARY 
Specimen Obtained result Expected Result % Total agreement 
Homozygous (FVL) Homozygous (2/2) Homozygous 100% 
Homozygous 
(PT20210) 
Homozygous (1/1) Homozygous 100% 
Heterozygous (FVL) Heterozygous (37/37) Heterozygous 100% 
Heterozygous 
(PT20210) 
Heterozygous (17/17) Heterozygous 100% 
Normal (FVL) Normal (31/31) Normal 100% 
Normal (PT20210) Normal (51/51) Normal 100% 
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With the additional fifteen (15) frozen samples, thirteen (13) samples correlated with 
previous verified results, two (2) samples were interpreted as invalid probably due to gross 
hemolysis and/or loss of integrity.  A frozen sample is unlikely to be used primarily because 
serum or plasma is the preferred sample for testing. 
The overall accuracy and precision performance of GeneXpert technology using whole 
blood sodium citrate and EDTA samples demonstrate 100% agreement with the predicate 
method, Invader chemistry.  Cepheid GeneXpert yielded a 98.06% performance agreement with 
the inclusion of frozen samples for a possible alternative sample type but determined not to be 
used. 
IQCP SUMMARY 
 The implementation of IQCP for the detection of both the FV Leiden and PT20210 
mutation using GeneXpert technology will assure the accuracy of the test result through the 
assessment of the pre-analytical, analytical, post-analytical phases of testing. The risk assessment 
outcome involving the six (6) components suggest probable risk occurring during pre-analytical 
testing such as mislabeled specimens, sample contamination, and personnel competency (Table 
5). This risk can be mitigated through adequate personnel training, the creation of appropriate 
procedure with emphasis on correct sample requirement and adherence to daily, weekly and 
monthly maintenance guidelines  
 External Quality control was also evaluated for the span of thirty-one (31) days for the 
determination of a customized plan to modify quality control frequency. It is used to assess 
instrument performance, the stability of cartridge kits and to save cartridge costs. Controls 
consist of normal, heterozygous and homozygous types. A total of 25 results were reviewed and 
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demonstrated no QC failure or within an acceptable performance, therefore the established 
customized external QC frequency will be set to perform every 31 days which is based on the 
College of American Pathologist  (CAP) common checklist guideline,  for every new lot of 
reagent kit, every new shipment of reagents and for any needed troubleshooting purposes. 
Furthermore, the implementation of a quality assessment program will review all activities 
mentioned in the IQCP and provide corrective actions, as needed, in order to measure its 
effectiveness and modification in the case of new errors that are detected or identified. (Table 7) 
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TABLE 5 RISK ASSESSMENT SUMMARY 
  
Possible Sources of Error 
Frequency of 
Occurrence 
Phase Severity Risk 
Acceptable 
Y/N 
Mitigations 
1.0 Specimen           
1.1 Mislabeled sample Probable 
Pre-
analytical 
 Serious N 
Delta check, 
history 
1.2 
Collection/Container/Volume Occasional 
Pre-
analytical Minor Y 
Adhere to 
guidelines 
detailed in the 
procedure 
1.3 Improper Storage Occasional 
Pre-
analytical Minor Y 
Rejection 
criteria-refer 
to SOP/ 
Training 
1.4 Transport Occasional 
Pre-
analytical Minor Y 
Redraw 
sample- 
Remedial 
actions for 
mishandling 
1.4 Integrity Occasional Analytical Minor Y 
Repeat/redraw 
sample 
2.0 Reagents           
2.1 Receiving and Storage           
 Occasional 
Pre-
analytical serious Y 
24hour 
temperature 
monitoring 
2.2 Expiration Dates           
 Unlikely 
Pre-
analytical Minor Y Replace kit 
2.3 Quality Control Unlikely Analytical Negligible Y 
the system will 
not run/ visual 
inspection 
      
      
14 
 
Possible Sources of Error 
Frequency of 
Occurrence 
Phase Severity Risk 
Acceptable 
Y/N 
Mitigations 
 
3.0 Testing Personnel           
3.1 Training & 
Competency Assessment Probable Analytical Serious N 
Annual 
Competency 
Evaluation and 
monitoring 
3.2 Labeling & Cartridge 
handling Occasional Pre-analytical Minor Y 
Direct 
observations of 
handling, 
Competency 
Evaluation 
3.2 Proficiency Testing- 
Failure due to Instrument 
Malfunction Unlikely Analytical Unlikely Y 
All PT failures 
are addressed 
and investigated 
          
3.2.1 CAP PT procedure 
not followed/PT not 
handled in the same 
manner as a patient 
sample Occasional Analytical Negligible Y 
Provision of 
instruction to 
testing 
personnel/ 
signed an 
attestation form 
          
3.3 Staffing- Inadequate 
to perform testing Unlikely Analytical Negligible Y 
Sample can be 
stored for 15 
days w/ temp. 
monitoring 
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Possible Sources of Error 
Frequency of 
Occurrence 
Phase Severity Risk 
Acceptable 
Y/N 
Mitigations 
4.0 Test system           
4.1 Contamination Unlikely Analytical Negligible Y 
Remove and; used 
new 
         
cartridge if 
necessary 
4.2 System errors- Pressure, 
air bubbles, temperature, 
optical signal, 
communication Occasional Analytical Negligible Y 
System checks; 
Follow maintenance  
         procedure 
4.3 Defective Cartridge  Occasional Analytical Negligible Y 
Visual Check, Repeat 
with new cartridge 
kit 
          
4.5 Defective modules Occasional Analytical Negligible Y 
Disable the module; 
Call Technical 
          support 
            
5.0 Environment           
5.1 Temperature/airflow/ 
humidity/ventilation Unlikely Pre-analytical Negligible Y 
Appropriate 
environmental 
conditions 
maintained 
5.2Sample/Amplicon 
Contamination Unlikely Pre-analytical Serious N 
Procedure for 
proper 
decontamination 
5.3 Maintenance Unlikely Pre-analytical Negligible Y 
Criteria defined in 
procedure 
5.4 Electric  Unlikely Pre-analytical Negligible Y 
Connected to UPS 
power supply 
 5.5 Defective Cartridge Occasional  Analytical  Negligible  Y 
Visual check, 
Internal control 
failure “Invalid” 
6.0 Test Results           
6.1 Review results Unlikely post-analytical Minor-Critical Y 
Auto-transmission 
of results/delta 
check 
6.2 Providers Complaints/ Unlikely post-analytical Minor N 
Investigate/Review 
IQCP/Modify 
Inquiries           
6.3 Release of results Unlikely Post-analytical 
Negligible to 
serious N 
Criteria defined in 
procedure 
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TABLE 6 SUMMARY OF QCP 
 
  
Type of Quality Control Frequency Criteria for Acceptability 
Testing of appropriate 
external QC before or 
concurrently when in use 
 Each new lot 
 Each new shipment 
 Monthly 
 PM/software upgrade 
Results are within specified 
QC range 
Any QC failure is 
investigated immediately, 
addressed by the QC CLS to 
QC Manager and/or 
Supervisor 
Instrument Preventive 
maintenance 
 Daily (each day of 
use) 
 Weekly and as needed 
 Monthly and as 
needed 
Meet acceptable criteria as 
defined in the Cepheid 
maintenance section  
Room Temperature check 
Refrigerator Temp check 
24/7 continuous monitoring 20-25 degrees C 
2-8 degrees C 
Inter-instrument correlation Every 6 months Correlation of test result and 
External QC testing on both 
GeneXpert instrument 
User training/Competency  Each new user and 
users prone to errors 
Initial, 6 months and annual 
Training checklist completed 
 
Pass all 6 elements of 
assessment 
PT assessment survey- TPM Two- Three 
times/year 
>80% score 
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TABLE 7 SUMMARY OF QA ACTIVITY 
 
COSTS SAVING  
Preventive Maintenance cost- The elimination of seven (7) instruments that includes 
two (2) EZ instruments for DNA isolation, three (3) thermal cyclers for amplification and two (2) 
Tecan readers for sample detection will save an estimated amount of $10,000.00 per year for 
preventive maintenance cost and other additional expense for other instrumentation problems.  
Frequency QA Activity 
Daily Daily review of the patient's result for reporting errors and/physician 
complaints. Investigate and initiate occurrence management report (OMR) 
 Confirmation of successful result transmission. Review BRL 
 Monitor Review queue for aberrant/unusual results. 
Weekly Audit GeneXpert PM charts for compliance 
 Review any new lot or shipment QC, as applicable 
Monthly Review monthly QC Data. Initiate corrective action(s) and revise QCP when 
unexpected QC failures indicate an adjustment to the QC plan defined. 
 Review Isensix temperature logs and perform corrective actions when 
indicated, appropriately documented. 
 Review of all equipment maintenance/ monitoring logs according to SOP 
 Review PT Scores and evaluate shift trends. Initiate corrective action as 
needed 
 Perform regular training and user competency assessment based on protocols, 
modify if necessary 
 Monitor pre-analytic quality indicators that address specimen handling and 
erroneous specimen labeling. Take corrective action needed 
 
Annually Review manufacturer’s instruction for any changes or updates 
 Confirm current procedure are available to users 
 Confirm procedure accuracy and clarity 
As needed Update procedures, training checklist and/or competency form 
 Follow up on complaints; Investigates the root cause(s) of error correction 
 Examine reasons for QC failures, PT failures and patient isolate reporting 
errors and address, as needed, in a new/updated risk assessment: 1) Has a new 
risk factor been identified? 2) Does this change the frequency of risk? 3) Does 
the risk change the potential severity of harm of patient? 
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Turnaround Time (TAT)- GeneXpert Sample processing time is about thirty-two (32) 
minutes for each test. Patients sample results are verified each day of testing and are available 
within 24 hours compared to the current method that has 4-5 hours of processing time and 5 -7 
days TAT. 
Personnel Utilization and Risk of Injury- With the GeneXpert technology system, it 
utilizes only one (1) CLS equivalent to a 0.5 FTE who is performing a two (2) step process 
involving sample pipetting, dispensing into the cartridge and then loading it directly into the 
instrument module. With the current PCR method, the processing time is 4-6 hours requiring a 
1.0 FTE. The process involves multiple users to perform the tests with three (3) different 
instruments causing an increased risk of personal injury due to a repetitive range of motion and 
potential manual entry errors that may affect patient management. Summary of comparison 
between GeneXpert and current method are detailed in a table form. (Table 8) 
TABLE 8 COMPARISON OF GENEXPERT VS CURRENT PCR METHOD 
  
Comparison GeneXpert Technology Current PCR Method 
Actual sample DNA 
Isolation/ 
Not performed, occurs inside 
the kit 
30 minutes per sample 
DNA 
Amplification/Detection 
Performed within the 
cartridge kit 
4.5 hours 
Reporting Manually entered, interpreted 
and verified 
Result automatically transmit 
and batch verified 
Pipetting 2 step pipetting 12 step pipetting 
Instrument used 1 3 
Personnel needed 0.5 FTE /shift 1.0 FTE/shift 
Turnaround time (TAT) 24 hrs 5 – 7 days 
Staff injury (Repetitive 
pipetting) 
Decreased/ rare Increased/ high probability 
Preventive Maintenance (# of 
instruments) 
1 instrument per year 7 instruments per year 
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DISCUSSION 
Thrombophilia is defined as an increased risk or tendency to develop blood clots as a 
result of predisposing factors that may be inherited or acquired. It is usually related to the 
abnormality of the clotting system of some individuals causing DVT or pulmonary embolism. 
The determination of both Factor V Leiden and PT20210 mutation using GeneXpert technology 
gives molecular testing a different perspective from usual standard PCR testing. The test is 
moderately complex, but the assay is a simple 2 step process that it can be performed by 
personnel with less background in molecular testing. It is a fast, single test assay that eases 
workflow and delivers same day test results to the clinicians. The technology allows flexibility to 
perform other tests for the benefit of better patient management and treatment. 
With the approval of the laboratory medical director for the IQCP implementation, the 
risk assessment analysis reinforces the accuracy of test results thru the detection of possible 
sources of error throughout the three (3) phases of testing. It is enhanced by a customized quality 
control plan and a comprehensive quality assessment that will be reviewed and monitored as 
indicated in the QC and QA summary. All necessary corrective action will be applied and 
implemented to mitigate prevent failures and probable sources of error. 
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CONCLUSION 
Given its heterogeneity of clinical expressions and still lack of gold standard of testing, 
the Cepheid GeneXpert technology will improve the management of individuals who have the 
greatest probability of having venous thromboembolism caused by the genetic mutations of 
Factor V Leiden and PT20210 variants. Result turnaround time is reduced to 24hrs, prevents 
potential staff injury from repetitive motion and promote cost saving for labor and instrument 
maintenance. 
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